Overview

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Status:
Completed

Trial end date:
2019-05-03

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Tenofovir
Vesatolimod